News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 30, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 27, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 11, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Conference Call and Webcast Today, May 6 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--May 6, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--May 5, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 29, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 9, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 7, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 24, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update
Conference Call and Webcast Today, February 20 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Feb. 20, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
TOP